Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial

Table 1 Adequate doses for selective serotonin receptor inhibitor (SSRI) and serotonin and noradrenaline receptor inhibitor (SNRI) antidepressants – table showing the list of adequate doses of SSRI/SNRI antidepressants used in the MIR study

Name	Trade name	Type	BNF^a Code	Minimum adequate daily dose (mg)
Citalopram	Cipramil	SSRI	4.3.3	20
Duloxetine	Cymbalta/ Yentreve	SNRI	4.3.4	60
Escitalopram	Cipralex	SSRI	4.3.3	10
Fluoxetine	Prozac	SSRI	4.3.3	20
Fluvoxamine	Faverin	SSRI	4.3.3	100
Paroxetine	Seroxat	SSRI	4.3.3	20
Sertraline	Lustral	SSRI	4.3.3	100
Venlafazine	Effexor	SNRI	4.3.4	75

^aSource: British National Formulary (BNF) No.55 (March 2008) for BNF code and dosage. These minimum doses were chosen to reflect prescribing guidance in UK primary care, and with expert advice from psychopharmacologists

ISSN: 1745-6215